Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT06710015
Starting soon Observational

Study on Fertility Parameters in Women With Germline Variants in BRCA1 and BRCA2

NCT06710015 · tracked via the Priya Life Science Italy tracker
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase
Observational
Started
2024-12-01
Last updated
2024-11-29

Condition(s) studied

BRCA1 and/or BRCA2 Variant CarriersFertilityReproductive AgeMenopausePregnancy Outcomes

Study summary

Pathogenic variants (PVs) in the BRCA1 and BRCA2 genes are associated with an increased risk of developing breast and ovarian cancers. According to current guidelines from the National Comprehensive Cancer Network, the risk of developing breast cancer exceeds 60% for both genes, while the risk for ovarian cancer ranges from 39% to 58% for the BRCA1 and from 13% to 29% for the BRCA2. The detection of a pathogenic variant in the BRCA1 or BRCA2 genes necessitates both the establishment of appropriate primary and secondary surveillance measures for carriers and the discussion of the familial implications of such findings.

The molecular basis initially suggesting a possible association between germline variants in BRCA1 and BRCA2 genes and diminished ovarian reserve lies in the cellular impact of impaired or defective repair of DNA double-strand breaks (DSBs) on oocytes. Notably, BRCA1 and BRCA2 genes play a key role in the ATM-related mechanism for DSB repair through the homologous recombination (HR) pathway.

Although preclinical evidence supports a potential correlation between defective DSB repair and normal follicle maturation processes, clinical studies on large cohorts of patients with pathogenic BRCA1 and BRCA2 variants yield inconsistent results. This discrepancy is likely attributable to the inherent challenges in recruiting a sufficiently homogeneous and statistically significant sample size.

The aim of the study is to evaluate reproductive capacity in women carrying pathogenic variants in the BRCA1/2 genes by assessing the number of pregnancies during the period from January 1, 2018, to December 31, 2023. Secondary objectives include evaluating menopausal characteristics and pregnancy outcomes.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
100 Years
Healthy volunteers
No
BRCA1 and BRCA2 carriers Inclusion Criteria: * age \> 18 years * presence of a pathogenic variant in the BRCA genes * signed informed consent Exclusion Criteria * presence of a pathogenic variant in another gene (not BRCA) * significant psychiatric or clinical impairment affecting the ability to consent to the study Control cohort Inclusion Criteria: \- Relatives up to the third degree of the first cohort who tested negative on predictive testing for the familial pathogenic variant in the BRCA genes, matched for age where possible. Exclusion Criteria: * absence of a pathogenic variant in another gene (non-BRCA) found in a family member * significant psychiatric or clinical impairment affecting the ability to consent to the study

Primary outcome measure(s)

  • Evaluate the reproductive capacity in women carrying PVs in BRCA1/2 genes — 1 year
    Evaluate number of pregnancies

Trial sites (1)

FacilityCityRegionStatus
UOC Genetica Medica Fondazione Policlinico Universitario A.Gemelli IRCCS Roma RM

More Fondazione Policlinico Universitario Agostino Gemelli IRCCS trials in Italy

Spatial Radiogenomics of Ovarian Cancer Recruiting
Cardiovascular Health in Adult Patients With Cancer Exposed to Cardiotoxic Therapies Recruiting
Echocardiographic Characterization of Cardiac Amyloidosis Recruiting
ECT STUDY High-grade or Initially Invasive Vulva - GinOnc-ECT Study Active, not recruiting
Youth Suicide Risk Factors, Reduction of Suicide Risk Factor in Youth People Recruiting

Other trials for the same condition

MicroRNA and Markers and Therapeutic Response to Romosozumab and Abaloparatide in Postmenopausal Osteoporosis Recruiting
Inflammation, Autoimmunity and Healthy Ageing in Menopause Transition. An Observational, Cross-sectional Study Starting soon
Mediterranean Diet on Pregnancy and Foetus Development Recruiting
MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse. Recruiting
Reproductive Prognosis in Women Seeking Offspring After Medical or Surgical Therapy for Endometriosis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06710015 on ClinicalTrials.gov ↗ ← All trials in Italy